Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow PODD
Insulet Corporation (PODD) EBITDA
Insulet Corporation's EBITDA for fiscal 2025 was $564.2M, up 44.8% from $389.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was $615.0M. Over the past ten years it has ranged from −$32.9M (fiscal 2015) to $564.2M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. Insulet Corporation ranks 14th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $564.2M | 44.78% |
| FY2024 | $389.7M | 33.05% |
| FY2023 | $292.9M | 190.58% |
| FY2022 | $100.8M | (45.04%) |
| FY2021 | $183.4M | 71.56% |
| FY2020 | $106.9M | 37.23% |
| FY2019 | $77.9M | 81.16% |
| FY2018 | $43.0M | 561.54% |
| FY2017 | $6.5M | 107.73% |
| FY2016 | $3.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $156.4M | 5.46% |
| Mar 2026 | $148.3M | (13.07%) |
| Dec 2025 | $170.6M | 22.12% |
| Sep 2025 | $139.7M | (2.58%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $2.6B |
| GMED Globus Medical, Inc. compare | $932.9M |
| PODD Insulet Corporation | $615.0M |
| HAE Haemonetics Corporation compare | $273.8M |
| PEN Penumbra, Inc. compare | $204.5M |
| BRKR Bruker Corporation compare | $199.5M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $53.1M |
| BIO Bio-Rad Laboratories, Inc. compare | $53.1M |
| GKOS Glaukos Corporation compare | −$148.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on PODD
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement